NASDAQ · ENTX
Entera Bio Ltd.
$3.12+$0.02 (+0.65%)
Entera Bio Ltd.’s quoted price sits in the upper half of its reported 52-week range, 25.71% below the high.
Loading market information…
NASDAQ · IKT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Inhibikase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Inhibikase Therapeutics, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Inhibikase Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 27, 2025 |
| $0.88+980.0% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$0.65-71.05% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $5.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.12+$0.02 (+0.65%)
Entera Bio Ltd.’s quoted price sits in the upper half of its reported 52-week range, 25.71% below the high.
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
$19.00+$0.69 (+3.77%)
Greenwich LifeSciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.28% below the high.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$4.11-$0.12 (-2.72%)
eXoZymes, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.66% below the high.
$0.73-$0.09 (-11.32%)
Estrella Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.87% below the high.
